tbuckley/cabot-search huggingface dataset:
Abstract 9032: Restoration of Normal Cardiomyocyte Basal and β-Adrenergic Receptor (AR) Subtype Modulation in Diabetic Cardiomyopathy by Chronic Selective Beta3-AR Antagonist in a Mouse Model of Type 2 Diabetes
Authors: Jing Cao, Xiaoqiang Sun, Heng Cheng, Yixi Liu, Zhe Chen, David Zhao, Donald McClain, Dalane W Kitzman, Che Ping Cheng
Journal: Circulation (2021)

Background: We have shown that L-748,337 (L-7), a selective β 3 -adrenergic receptor (AR) antagonist reversed LV dysfunction and β-AR desensitization in diabetes (DM) caused diabetic cardiomyopathy (DCM). The mechanism is unclear. Recent evidence suggests that normal myocardial performance depends on the balance in myocyte β 3 -, β 1 -, and β 2 -AR. Pivotal restructuring of β-AR system resulting in the decline of β-AR reserve plays a crucial role in DCM. We assessed the hypothesis that chronic L-7 would prevent DCM-induced abnormalities of β-AR subtype-stimulated regulation on intrinsic LV myocyte function and [Ca 2+ ] i regulation, thus restoring cardiac function. Methods: Studies were conducted in 3 groups of female mice: Type 2 DM (T2) (n=9), induced with high-fat diet (HFD) intake for 14 weeks (W), but after fed HFD for 4 W receiving streptozotocin (STZ, 40 mg/kg/day, i.p. for 5 days); T2/L-7 (n=7), T2 mice at 10 W received L-7 (10 -7 M/kg/day, mini-pump) for 4 W; and Controls (C)(n=9). We compared LV myocyte contractile and [Ca 2+ ] iT responses to β-AR subtype stimulation by random exposure of myocytes to Isoproterenol (ISO,10 -8 M) or a selective β 1 -, β 2 -, or β 3 -agonist, Norepinephrine (NE, 10 -7 M), Zinterol (ZIN, 10 -5 M) and BRL-37,344 (BRL, 10 -8 M), respectively, during drug perfusion. Results: T2 and T2/L-7 mice had mean blood glucose levels of 388 mg/dl and 369 mg/dl, respectively. Versus C, only in T2, basal LV myocyte contractility (dL/dt max , 76 vs 133 μm/s), relaxation and [Ca 2+ ] iT (0.16 vs 0.21) were significantly decreased. ISO-stimulated dL/dt max (40% vs 58%) was attenuated accompanied by a diminished NE-mediated increase in dL/dt max (28% vs 44%), but enhanced BRL-induced decreases in dL/dt max (29% vs 12%).The response of dL/dt max (24% vs 15%) to ZIN was increased. Importantly, in T2/L-7 myocytes, the basal dL/dt max (128 μm/s) and [Ca 2+ ] iT (0.21) remained close to control values with preserved β-stimulated positive modulation on cell contraction. The increases in dL/dt max in response to ISO (57%), NE (40%) or ZIN (15%) were similar to that in control myocytes, respectively. Conclusions: Chronic β 3 -AR antagonist reverses β-AR signaling defects, resensitizing the β-AR subtype system modulation on LV myocytes function, thus playing a salutary role in DCM.
Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications
Authors: Lubica Rauova, Andy Wang, Serge Yarovoi, Sanjay Khandelwal, Anand Padmanabhan, Olga Oleshko, Matthew J. Charman, Andreas Tiede, Charles S. Abrams, Matthew D. Weitzman, Gowthami M. Arepally, Douglas B. Cines, Mortimer Poncz
Journal: Blood (2021)
Characteristics and Outcomes of Products Seeking Competitive Generic Therapy Designation and Exclusivity
Authors: Harinder Singh Chahal, Annabelle C. Fowler, Rinku Patel, Martin Shimer
Journal: JAMA (2021)

This study describes the process used by the US Food and Drug Administration to review potential generic drugs for Competitive Generic Therapy (CGT) designation and marketing exclusivity as well as the characteristics and outcomes of products that have sought CGT designation and exclusivity from 2017-2020.
Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions
Authors: Ellen Madarang, Jillian Lykon, Wenhui Li, Sunil Iyer, Michele Stanchina, Nina Nguyen, Terrence Bradley, Mikkael A. Sekeres, Justin Taylor, Namrata Sonia Chandhok, Justin Watts
Journal: Blood (2021)
NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML
Authors: Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr
Journal: Blood (2021)
Isolated Changes in Chromatin Accessibility and Enhancer-Promoter Contacts at the β-Globin Locus Distinguish Fetal Hemoglobin Producing F-Cells from a-Cells
Authors: Eugene Khandros, Peng Huang, Scott A. Peslak, Malini Sharma, Osheiza Abdulmalik, Belinda Giardine, Zhe Zhang, Cheryl A. Keller, Ross C. Hardison, Gerd A. Blobel
Journal: Blood (2021)
The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study
Authors: Muhit Özcan, Ryan D. Cassaday, Pawan Singh, Ewa Zarzycka, Xin Zhang, Eric Nègre, Erik Vandendries, Fevzi Altuntas
Journal: Blood (2021)
Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT) in Children with Myelodysplastic Syndromes
Authors: Pietro Merli, Daria Pagliara, Tommaso Mina, Valentina Bertaina, Giuseppina Li Pira, Stefania Lazzaro, Simone Biagini, Federica Galaverna, Luisa Strocchio, Roberto Carta, Francesco Quagliarella, Marco Becilli, Emilia Boccieri, Francesca Del Bufalo, Arianna Panigari, Annalisa Agostini, Mattia Algeri, Marco Zecca, Franco Locatelli
Journal: Blood (2021)
Methodological and reporting quality of non-inferiority randomized controlled trials comparing antifungal therapies: a systematic review
Authors: Adam S. Komorowski, Anthony D. Bai, Anna Cvetkovic, Omar Mourad, Carson K.L. Lo, Xena X. Li, Vaibhav Mokashi, Aidan Findlater, D. Brody Duncan, Charlotte Fuller, Deborah Yamamura, Dominik Mertz
Journal: Clinical Microbiology and Infection (2021)
Comparison of Transplant Donor and Third-Party Donor Derived CMV-Specific T Cells for CMV Infection after Allogenic Stem Cell Transplantation
Authors: Xuying Pei, Xuefei Liu, Xiang-Yu Zhao, Yingjun Chang, Meng Lv, Xiaodong Mo, Yuqian Sun, Lanping Xu, Yu Wang, Xiaohui Zhang, Xiaojun Huang
Journal: Blood (2021)
Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis
Authors: Shehab Fareed Mohamed, Tareq Abuasba, Kelly S. Chien, Guillermo Montalban-Bravo, Faezeh Darbaniyan, Sherry A. Pierce, Kelly A. Soltysiak, Fadi Haddad, David McCall, Branko Cuglievan, Elias J. Jabbour, Naval Daver, Tapan M. Kadia, Naveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2021)
Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab
Authors: Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yañez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Florian Hiemeyer, Barrett H Childs, Yuankai Shi, Pier Luigi Luigi Zinzani
Journal: Blood (2021)
Conservatorship for gravely disabled psychiatric patients: a four-year follow-up study
Authors: H R Lamb, L E Weinberger
Journal: American Journal of Psychiatry (1992)

The authors examined the conservatorship process in California by studying a group of psychiatric patients for whom conservatorship was sought; their goal was to determine its effectiveness both during and after the period of conservatorship.The subjects were 60 county psychiatric hospital inpatients 18-60 years old for whom temporary (30-day) conservatorships were obtained and who were followed for 4 years. The patients' courses over the 4 years were assessed in terms of whether 1-year conservatorships were obtained, stability (number and length of psychiatric hospitalizations, arrests, serious physical violence, and homelessness), and presence or absence of family support.The patients proved to be a severely mentally ill and disabled group. Thirty-five (58%) were granted a 1-year conservatorship sometime during the 4-year study period, and 25 (42%) were not. Both family support and conservatorship appeared to be related to the patients' stability. When one or both were present, there was a significantly greater likelihood of stability.The authors believe that for a considerable number of chronically and severely mentally ill individuals, conservatorship would play an important role in their clinical management and treatment by helping to eliminate their chaotic life styles, their cycle of admission and discharge from hospitals and jails, and/or their living on the streets, particularly when family support is absent.
Machine intelligence in non-invasive endocrine cancer diagnostics
Authors: Nicole M. Thomasian, Ihab R. Kamel, Harrison X. Bai
Journal: Nature Reviews Endocrinology (2021)

Artificial intelligence (AI) has illuminated a clear path towards an evolving health-care system replete with enhanced precision and computing capabilities. Medical imaging analysis can be strengthened by machine learning as the multidimensional data generated by imaging naturally lends itself to hierarchical classification. In this Review, we describe the role of machine intelligence in image-based endocrine cancer diagnostics. We first provide a brief overview of AI and consider its intuitive incorporation into the clinical workflow. We then discuss how AI can be applied for the characterization of adrenal, pancreatic, pituitary and thyroid masses in order to support clinicians in their diagnostic interpretations. This Review also puts forth a number of key evaluation criteria for machine learning in medicine that physicians can use in their appraisals of these algorithms. We identify mitigation strategies to address ongoing challenges around data availability and model interpretability in the context of endocrine cancer diagnosis. Finally, we delve into frontiers in systems integration for AI, discussing automated pipelines and evolving computing platforms that leverage distributed, decentralized and quantum techniques. This Review explains core concepts in artificial intelligence (AI) and machine learning for endocrinologists. AI applications in endocrine cancer diagnostics are highlighted as well as research challenges and future directions for the field.
CXCR4 Drives Lympho-Myeloid Fate of Hematopoietic Progenitors <i>Via</i> mTOR and Mitochondrial Metabolic Pathways
Authors: Vincent Rondeau, Amélie Bonaud, Zeina Abou-Nader, Julia Lemos, Vanessa Gourhand, Marc Delord, Ghislain Bidaut, Adrienne Anginot, Nathalie Mazure, David H. McDermott, Véronique Parietti-Montcuquet, Niclas Setterblad, Nicolas Dulphy, Françoise Bachelerie, Daniel Stockholm, Michel Aurrand-Lions, Philip M. Murphy, Marion Espeli, Stéphane Mancini, Karl Balabanian
Journal: Blood (2021)
A Novel Lair-1 Antibody Selectively Targets Acute Myeloid Leukemia (AML) Stem Cells
Authors: Linjie Tian, Ana Paucarmayta, Rustin Lovewell, Karla Maloveste, Junshik Hong, Carly Hedgepath, Kwang Woon Kim, Ron Copeland, Thomas O'Neill, Shashank Patel, Linda N. Liu, Han Myint, Solomon Langermann, Dallas B Flies, Tae Kon Kim
Journal: Blood (2021)
Should all babies have their genome sequenced at birth?
Authors: Leslie G Biesecker, Eric D Green, Teri Manolio, Benjamin D Solomon, David Curtis
Journal: BMJ (2021)

The UK is set to pilot genetic sequencing in healthy babies. Genomic screening at appropriate ages could help reduce the burden of genetic disorders, say <b>Leslie Biesecker and colleagues</b>, but <b>David Curtis</b> argues that newborns cannot consent and that our most personal data might be misused
Abstract 9218: The Long Non-Coding Rna Caren Improves Cardiac Dysfunction in Aged Mice
Authors: Michio Sato, Keishi Miyata, Tsuyoshi Kadomatsu, Koichi Node, Yuichi Oike
Journal: Circulation (2021)

Background: Heart failure (HF) is the predominant cause of hospitalization and amongst the leading causes of death in developed countries. Especially, the prevalence of HFpEF is increasing and its ...
Discovery of TSC-101: A First-in-Class Natural HA-2-Specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy
Authors: Ribhu Nayar, Mollie M Jurewicz, Sonal Jangalwe, Hannah Bader, Kimberly M Cirelli, Andrew Basinski, Daniel Pollacksmith, Alexandra Luther, Cisem Karaca, Anna Labrozzi, Krista Daniel, Lisa Nip, Danielle Ramsdell, Amy Virbasius, Candace Perullo, Kenneth L Jahan, Sida Liao, Livio Dukaj, Alexandra Cristofaro, Shrikanta Chattopadhyay, Kenneth Olivier, Antoine J Boudot, Qikai Xu, Yifan Wang, Cagan Gurer, Gavin Macbeath
Journal: Blood (2021)
A Micro‐Environment Regulator for Filling the Clinical Treatment Gap after a Glioblastoma Operation
Authors: Yiwen Zhang, Haoyu You, Yaoben Wang, Qinjun Chen, Qin Guo, Yongchao Chu, Chao Li, Wenxi Zhou, Hongyi Chen, Peixin Liu, Yu Wang, Zhenhao Zhao, Zheng Zhou, Yifan Luo, Xuwen Li, Tongyu Zhang, Haolin Song, Chufeng Li, Boyu Su, Tao Sun, Yunke Bi, Lin Yu, Chen Jiang
Journal: Advanced Healthcare Materials (2021)

Abstract The rapid postoperative recurrence and short survival time of glioblastoma (GBM) patients necessitate immediate and effective postoperative treatment. Herein, an immediate and mild postoperative local treatment strategy is developed that regulates the postoperative microenvironment and delays GBM recurrence. Briefly, an injectable hydrogel system (imGEL) loaded with Zn(II) 2 ‐AMD3100 (AMD‐Zn) and CpG oligonucleotide nanoparticles (CpG NPs) is injected into the operation cavity, with long‐term function to block the recruitment of microglia/ macrophages and activate cytotoxic T cells. The finding indicated that the imGEL can regulate the immune microenvironment, inhibit GBM recurrence, and gain valuable time for subsequent adjuvant clinical chemotherapy.
Chemotherapy with the Use of TKIs Based on MRD Has the Potential to Avoid Hematopoietic Stem Cell Transplantation in Treatment for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Results of the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study ALL-Ph13
Authors: Atsushi Sato, Hirohide Kawasaki, Takao Deguchi, Yoshiko Hashii, Yuka Iijima-Yamashita, Sachiko Yonezawa, Chiyo K Imamura, Haruko Shima, Hirotoshi Sakaguchi, Yuichi Kodama, Keisuke Kato, Motohiro Kato, Hidefumi Hiramatsu, Nobutaka Kiyokawa, Akiko Kada, Akiko M Saito, Keizo Horibe, Atsushi Manabe, Hiroyuki Shimada
Journal: Blood (2021)
Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy
Authors: Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani
Journal: Blood (2021)
Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
Authors: Christian Hurtz, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll
Journal: Blood (2021)
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
Authors: Xiaofeng Chen, Deqiang Wang, Jing Liu, Jingrong Qiu, Jun Zhou, Jieer Ying, Yan Shi, Zhaoxia Wang, Haizhou Lou, Jiuwei Cui, Jingdong Zhang, Yunpeng Liu, Fengjiao Zhao, Lanlan Pan, Jianyi Zhao, Dongqin Zhu, Shiqing Chen, Xiangcheng Li, Xue Li, Liuqing Zhu, Yang Shao, Yongqian Shu
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Recently, immunotherapy with immune checkpoint inhibitors (ICIs) has shown promising efficacy in biliary tract cancer (BTC), which includes gallbladder cancer (GBC) and cholangiocarcinoma (CHOL). Understanding the association between immunotherapy outcomes and the genomic profile of advanced BTC may further improve the clinical benefits from immunotherapy. Methods Genomic tumor DNA was isolated from 98 Chinese patients with advanced BTC and used for targeted next-generation sequencing of 416 cancer-related genes to identify the genomic alterations common to advanced BTC. Thirty-four patients had received ICI camrelizumab plus gemcitabine and oxaliplatin (from the NCT03486678 trial) as a first-line treatment. Tumor-infiltrating immune cells were evaluated using immunofluorescence staining. Results KRAS and TP53 mutations were much more frequent in the advanced-stage BTC cohort than in other cohorts with mostly early stage disease. Specifically, KRAS-TP53 co-mutations were favored in advanced CHOL, with a favorable response to immunotherapy, while single KRAS mutations predicted poor prognosis and immunotherapy outcomes for CHOL. Compared with GBC, CHOL had more mutations in genes involved in KRAS signaling; a high mutation load in these genes correlated with poor immunotherapy outcomes and may subsequently cause inferior immunotherapy outcomes for CHOL relative to GBC. Furthermore, a genomic signature including 11 genes was developed; their mutated subtype was associated with poor prognosis and immunotherapy outcomes in both CHOL and GBC. Transcriptome analyses suggested immune dysfunction in the signature mutated subtype, which was validated by tumor microenvironment (TME) evaluation based on detection of immune cell infiltration. Importantly, the signature wild-type subtype with favorable TME may be an advantageous population of immunotherapy. Conclusions Genomic alterations in advanced BTC were associated with specific prognosis and immunotherapy outcomes. Combining genomic classification with TME evaluation further improved the stratification of immunotherapy outcomes.
Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation after Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Authors: Zhihui Li, Qinlong Zheng, Fan Wu, Caiyan Zhang, Teng Xu, Yongqiang Zhao, Yanzhi Song, Tong Wu
Journal: Blood (2021)
Increased Survival Disparities Among Children and Adolescents &amp; Young Adults with Acute Myeloid Leukemia: A Dutch Population-Based Study
Authors: Maya Schulpen, Bianca F. Goemans, Gertjan J.L. Kaspers, Marc H.G.P. Raaijmakers, Christian M. Zwaan, Henrike E. Karim-Kos
Journal: Blood (2021)
Abstract 8956: Association of Serum Irisin Levels with Inflammatory, Biochemical, and Cardiac Imaging Parameters in Patients With Chronic Heart Failure versus Controls
Authors: Eder Luna-Ceron
Journal: Circulation (2021)

Chronic heart failure (CHF) remains one of the most important causes of morbidity and mortality globally. Metabolic and energetic maladaptation has proven to play a critical in the progression of this condition. In this regard, evidence from preclinical studies has shown that irisin, a recently discovered adipomyokine involved in metabolic control, can induce positive cardioprotective effects by improving cardiac remodeling, cardiomyocyte viability, calcium delivery, and reduction of inflammatory mediators. However, data on the clinical associations between irisin levels and inflammatory and functional imaging parameters are scarce in CHF patients. 32 subjects diagnosed with CHF and 32 healthy controls were evaluated in a cross-sectional study. Serum irisin levels were significantly lower in patients with CHF (4.92, IQR [5.4] ng/ml) than controls (6.45, IQR [3.58] ng/ml). We identified a positive correlation between irisin levels and LVEF (R=0.3), fraction shortening (R=0.4), and body fat percentage (R=0.4). In contrast, a negative correlation between irisin levels and BNP (R=-0.4), insulin levels (R=-0.1), and HOMA index (R=-0.2) was reported. Subjects with CHF showed higher levels of TNF-α (22.05 IQR [12.28] pg/ml) and IL-12p70 (5.58 IQR [4.47] pg/ml) in comparison with controls (9.77 IQR [6.24] and 3.05 [1.90] pg/ml ), while controls showed higher levels of IL-10 (16.27 IQR [10.82] pg/ml) in comparison with CHF cases (7.51 IQR [8.47] pg/ml). However, we did not observe significant correlations between irisin levels and inflammatory cytokines. Irisin levels are possibly reduced in patients with CHF due to the intrinsic energetic and metabolic adaptations that occur as a result of the reduction of cardiac output. Reduced irisin levels play a synergic role with the effects of proinflammatory mediators by hazarding the cardiomyocyte viability, adaptation to ventricular remodeling, and response to fibrosis. This additional damage continues compromising cardiac dynamical parameters creating a vicious cycle.
A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)
Authors: Alvaro J. Alencar, Lindsey E. Roeker, Marc Hoffmann, Guru Subramanian Guru Murthy, Vishalkumar Patel, Nora C. Ku, James M. Pauff, Toby A. Eyre, Wojciech Jurczak, Steven Le Gouill
Journal: Blood (2021)
LKB1 Coordinates Metabolic Pathways to Maintain Homeostasis of Haematopoietic Stem Cells and Regulate Erythropoiesis
Authors: Shijie Zhang, Yuanlin Xu, Mingming Zhang, Jingxin Zhang, Peijun Jia, Yudong Li, Lulu Duan, Yan Li, Huan Zhang, Yating Li, Xiaoli Qu, Lixiang Chen, Xiuli An
Journal: Blood (2021)
Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas
Authors: N. Ari Wijetunga, Brandon S. Imber, Jisun Lee, Carla Hajj, Marius E Mayerhoefer, Heiko Schoder, Joachim Yahalom
Journal: Blood (2021)
Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients
Authors: Ashley Matuszfisher, Rupali Bose, Danielle Boselli, Gray Magee, Tommy Chen, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Edward A. Copelan, Belinda Avalos, James T Symanowski, Derek Raghavan, Ryan Jacobs, Nilanjan Ghosh
Journal: Blood (2021)
CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors
Authors: Stefania Fusani, Alessandra Rossi, Saveria Mazzara, Elena Baiardi, Francesca Zammarchi, Patrick H van Berkel, Stefano A Pileri, Corrado Tarella, Enrico Derenzini
Journal: Blood (2021)
A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial
Authors: Marco Ladetto, Simone Ferrero, Ilaria Del Giudice, Sara Galimberti, Valter Gattei, Luigi Marcheselli, Barbara Mantoan, Elisa Genuardi, Beatrice Alessandria, Martina Ferrante, Irene Dogliotti, Irene Della Starza, Lucia Anna De Novi, Marzia Cavalli, Susanna Grassi, Elena Ciabatti, Francesca Guerrini, Riccardo Bomben, Massimo Degan, Eva Zaina, Tommasina Perrone, Mario Petrini, Francesca Re, Attilio Olivieri, Sara Veronica Usai, Donato Mannina, Brunangelo Falini, Delia Rota Scalabrini, Pietro Maria Stefani, Filippo Ballerini, Massimo Federico, Stefano Luminari
Journal: Blood (2021)